Protein Summary
Lectin which functions in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). May bind terminally misfolded non-glycosylated proteins as well as improperly folded glycoproteins, retain them in the ER, and possibly transfer them to the ubiquitination machinery and promote their degradation. Possible targets include TRPV4. This gene encodes a protein that is highly expressed in osteosarcomas. This protein binds to the hypoxia-inducible factor 1 (HIF-1), a key regulator of the hypoxic response and angiogenesis, and promotes the degradation of one of its subunits. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
- ENST00000257966
- ENSP00000257966
- ENSG00000135506
- ENST00000315970
- ENSP00000318165
- ENST00000389142
- ENSP00000373794
- ENST00000389146
- ENSP00000373798
- ENST00000435406
- ENSP00000389632
- ENST00000439210
- ENSP00000407360
- ENST00000551035
- ENSP00000447866
- ENST00000552285
- ENSP00000450010
- OS-9
- ERLEC2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
disease perturbation | 0.93 | ||
kinase perturbation | 0.88 | ||
transcription factor binding site profile | 0.88 | ||
transcription factor perturbation | 0.88 | ||
cellular component | 0.71 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 73.6 (req: < 5)
Gene RIFs: 21 (req: <= 3)
Antibodies: 252 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 73.6 (req: >= 5)
Gene RIFs: 21 (req: > 3)
Antibodies: 252 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 12
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0